Ashish Sarraju, Xiaolin Du, Luping Zhou, Luke J Laffin, Kathy Wolski, Yumei Gu, Ziyang Liu, Qinsheng Zhang, Kunyuan Cui, Xiaolan Yong, Steven E Nissen
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 90
- Comments 0
Advertisement
[Articles] Safety and lipoprotein(a)-lowering effects of Kylo-11, a non-canonical, long-duration small interfering RNA targeting lipoprotein(a): a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial
Journal content Created on 28 Aug 2026 The Lancet
Advertisement